Pseudovirus News and Research

RSS

Mucosal IgA fused nanobody as a non-invasive, cost-effective prophylaxis and therapeutic option against major SARS-CoV-2 variants

Researchers from the United States developed an affordable, non-invasive, inhalable prophylactic treatment consisting of immunoglobulin (Ig) A fused nanobodies against the SARS-CoV-2 Omicron variant.

2 Dec 2022

Plasma from vaccinated and COVID-19 convalescent subjects as passive immunotherapy against the new Omicron BQ.1.1, XBB, and BF.7 variants

Researchers systematically reviewed SARS-CoV-2 Omicron BQ.1.1 neutralization data from individual patient samples.

30 Nov 2022

Broadly cross-reactive antibodies that protect from SARS-CoV-2 variants are revealed by virus coldspot-driven discovery

A recent study identified neutralizing antibodies against conserved SARS-CoV-2 epitopes.

30 Nov 2022

Nanoparticles displaying SARS-CoV-1 and SARS-CoV-2 spikes induce broad antibody responses in animal model

A recent study published in the journal iScience reported that nanoparticles (NPs) co-displaying spike proteins from different sarbecoviruses improve the breadth of neutralizing responses.

27 Nov 2022

The safety and immunogenicity of a fourth dose of NVX-CoV2373

Researchers assessed the immunogenicity and safety of a fourth homologous boost dose of a recombinant SARS-CoV-2 spike protein vaccine called NVX-CoV2373.

23 Nov 2022

The binding and functional serologic responses to COVID-19 vaccination in children with history of MIS-C

Researchers evaluated the serological responses elicited by COVID-19 vaccinations in children who developed MIS-C following a previous SARS-CoV-2 infection.

23 Nov 2022

Potent hypervalent nanoparticles against HIV, Lassa and SARS-CoV-2 variants

In a recent study published in the journal Advanced Science, researchers developed molecularly imprinted nanoparticles (nanoMIPs) with broad-spectrum activity against lethal viruses.

21 Nov 2022

Bispecific antibodies neutralize Sarbecoviruses with increased breadth and potency

In a recent study posted to the bioRxiv* preprint server, researchers developed bispecific antibodies (bsAbs), neutralizing severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants.

17 Nov 2022

Researchers identify a conserved site on SARS-CoV-2 spike that a broadly neutralizing macrocyclic peptide can target

Researchers explored the efficiency of a macrocyclic peptide in inhibiting the SARS-CoV-2 spike protein.

17 Nov 2022

SARS-CoV-2 ‘Deltacron’ variant exhibits immune-escape properties similar to Omicron BA.1

The SARS-CoV-2 Deltacron does not exhibit higher transmissibility or immune evasion than the Omicron BA.1 variant.

16 Nov 2022

Development of a potent, broadly protective vaccine against all SARS-CoV-2 variants

In a recent study published in the journal npj Vaccines, researchers in China designed, produced, and evaluated the neutralization efficacy of a recombinant coronavirus disease 2019 (COVID-19) vaccine containing four hot-spot substitution mutations based on a prefusion-stabilized severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein (S) trimer.

15 Nov 2022

Researchers discover new antiviral compounds derived from two Korean native plants

Codonopsis lanceolata, more commonly referred to as "deodeok", is used as a medicinal herb in South Korea.

11 Nov 2022

Mosaic nanoparticles displaying spike protein trimers from different coronaviruses elicits cross-reactive protection

In a recent study under review at the Nature Portfolio journal and currently posted to Research Square* preprint server, researchers developed and assessed the immunogenicity of nanoparticles expressing spike trimers from coronaviruses (CoVs).

10 Nov 2022

How does imprinted SARS-CoV-2 humoral immunity drive convergent Omicron evolution?

Researchers examined how imprinted SARS-CoV-2 humoral immunity drives convergent evolution in continuously emerging Omicron subvariants.

2 Nov 2022

Exploring the safety and immunogenicity of KD-414, a novel SARS-CoV-2 vaccine

In a new study, researchers assessed the immunogenicity and safety of KD-414, an inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine.

1 Nov 2022

Combination of multi-specificity and antibody avidity enhances protection against SARS-CoV-2

In a recent study posted to the bioRxiv* preprint server, an international team of researchers leveraged the human light chain apoferritin protomer-derived MULTI-specific, multi-Affinity antibody (Multabody, MB) platform for the generation of broad and potent SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2)-neutralizing antibodies (Abs).

27 Oct 2022

Updapted BA.4/5 COVID vaccines boost protection but might not surpass original formula

In a recent study posted to the bioRxiv* preprint server, researchers at Beth Israel Deaconess Medical Center assessed the immunogenicity associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BA.5 bivalent messenger ribonucleic acid (mRNA) vaccine boosters.

27 Oct 2022

Omicron BA.4/BA.5 bivalent mRNA vaccine booster elicits similar neutralizing antibody responses to monovalent vaccine

Researchers analyzed the antibody response induced by the new bivalent mRNA SARS-CoV-2 vaccines in individuals who have been fully vaccinated with monovalent vaccines and those who have had breakthrough infection with the SARS-CoV-2 Omicron BA.4/BA.5 variants.

26 Oct 2022

DNA damage in older age increases expression of ACE2 and SARS-CoV-2 infection risk

Impaired DNA repair capacity among elderly increases expression of ACE2 receptor.